📰 Partial Response News
Page 3 - Partial Response News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Partial Response. Real-time updates on events, politics, business and more.
February 13, 2023
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...
December 15, 2022
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock Next generation anthracycline,...
December 8, 2022
08.12.2022 - Immunocore presents ovarian cancer expansion data for ImmTAC candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4 expression IMC-C103C has a manageable safety ... Seite 1
November 30, 2022
30.11.2022 - TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) - Theralase Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic ...
November 10, 2022
Investegate announcements from Syncona Limited, Anaveon presents updated data from ANV419
July 6, 2022
BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 -- Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse... | July 6, 2022
May 26, 2022
Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor...
February 25, 2022
/PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics,...
February 25, 2022
DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the developm...
February 25, 2022
DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ — PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of...